• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Thoratec’s Q4, 2014 earnings beat forecasts

Thoratec’s Q4, 2014 earnings beat forecasts

February 11, 2015 By Brad Perriello

Thoratec's Q4, 2014 earnings beat forecasts

Thoratec (NSDQ:THOR) yesterday reported higher-than-forecast earnings for the 4th quarter and 2014, crediting an extra selling week and better utilization rates for its implantable heart pumps.

Pleasanton, Calif.-based Thoratec posted profits of $11.8 million, or 21¢ per share, on sales of $128.0 million for the 3 months ended Jan. 3, for a bottom-line slide of 9.3% on a sales decline of 0.2%.

But adjusted to exclude 1-time items, earnings per share reached 39¢, a full 15¢ ahead of expectations on Wall Street. Full-year profits were off 31.3% to $50.4 million, or 89¢ per share, on a sales decline of 5.0% to $477.6 million, but again adjusted EPS came in ahead of The Street’s $1.26 prediction, at $1.40.

"Our 4th-quarter results marked a good 1st step toward stabilizing revenue growth with results driven by higher utilization of HeartMate II during the quarter," president & CEO Keith Grossman told analysts during a conference call yesterday. "For those of you who have watched this market as long as I have, you know that 1 quarter doesn’t make a trend. That said, we were very pleased to see a re-emergence of market growth during the quarter and we’re also generally pleased with some improvement relative to our recent market share trends and we’re certainly going to press to build off this momentum going forward."

Thoratec said it expects to log adjusted EPS of $1.10 to $1.20 on sales of $450 million to $460 million this year.

Grossman also said the company is narrowing its focus to the ventricular assist device market, discontinuing its work on a structural heart tool and "rescoping" another R&D project.

"Specifically, we’ve moved forward with the decision to discontinue commercialization of the Apica structural heart tool, while at the same time remaining very committed to the continued development of the Apica VAD tool," Grossman said.

Thoratec inked a $75 million deal for Apica Cardiovascular last summer, a year after buying the DuraHeart II heart pump from Terumo Corp. (TYO:4543) in a deal worth up to $43.5 million.

"This decision will save around $4 million of annual operating expense, but more importantly will allow us to focus solely on the VAD-related product that serves as both the strategic rationale and nearly the entire valuation basis of this [Apica] acquisition. Additionally, we’ve moved forward with rescoping the DuraHeart II R&D project that we acquired during 2013. This decision followed a reassessment of how the DuraHeart technology could best fit into our long term product pipeline cadence," Grossman explained.

Filed Under: MassDevice Earnings Roundup, News Well, Structural Heart Tagged With: 2014, Apica Cardiovascular, Q4, Terumo, Thoratec Corp.

More recent news

  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy